如何使质母细胞瘤对temozolomide化疗敏感:以差距为中心的观点
Alila Miramova1, Anton Gartner1,2,3, Dmitri Ivanov3
1Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea.
Frontiers in cell and developmental biology
|July 16, 2024
概括
对质母细胞瘤的Temozolomide (TMZ) 化疗面临阻力. 针对DNA修复途径,如那些涉及MGMT和MMR的途径,以及PARP抑制剂,可以通过创建有毒的DNA空白来重新使瘤对TMZ敏感.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 泰莫佐洛米德 (Temozolomide,简称TMZ) 是用于质母细胞瘤的主要化疗.
- 癌细胞对TMZ产生耐药性,需要新的治疗策略.
- TMZ诱导DNA基导,包括O-meG和3-meA,影响DNA复制.
研究的目的:
- 根据DNA修复途径区分TMZ敏感和耐药的质母细胞瘤.
- 通过针对特定的DNA修复机制,探索增强TMZ疗效的策略.
- 调查单链DNA (ssDNA) 缺口作为常见漏洞的作用.
主要方法:
- 审查有关TMZ机制和DNA修复途径的现有文献.
- 基于MGMT和MMR状态的质母细胞瘤亚型的分析.
- 讨论PARP抑制剂 (PARPi) 和它们在TMZ强化中的潜力.
主要成果:
- 对TMZ敏感的质母细胞瘤 (MGMT阴性,MMR熟练) 通过O-meG/T对的徒劳的不匹配修复被杀死.
- 耐TMZ的质母细胞瘤 (MGMT阳性或MMR缺乏) 需要更高的TMZ剂量,被复制阻断3-meA杀死.
- 在敏感细胞和耐药细胞中,ssDNA缺口作为关键毒性中间体出现,类似于BRCA缺陷癌症.
结论:
- 根据DNA修复能力区分质母细胞瘤亚型对于有效的TMZ治疗至关重要.
- 抑制特定的DNA修复途径 (例如MGMT,MMR,PARP1,APE1) 可以使质母细胞瘤对TMZ敏感.
- 向DNA修复为克服TMZ抵抗在质母细胞瘤治疗中提供了一个有希望的途径.
相关概念视频
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


